Iterum Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
9
- Stock Symbol
-
ITRMF
Iterum Therapeutics General Information
Description
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Contact Information
Website
www.iterumtx.comCorporate Office
- 25 North Wall Quay
- Dublin D01 H104
- Ireland
Corporate Office
- 25 North Wall Quay
- Dublin D01 H104
- Ireland
Iterum Therapeutics Timeline
Iterum Therapeutics Stock Performance
As of 04-Aug-2026, Iterum Therapeutics’s current market cap is $533.00 with 53.3M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $533.00 | 53.3M | 96.5K | -$0.76 |
Iterum Therapeutics Financials Summary
As of 30-Sep-2025, Iterum Therapeutics has a trailing 12-month revenue of $390K.
|
In Thousands, USD |
TTM 30-Sep-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 49,452 | 56,637 | 10,169 | (23,864) |
| Revenue | 390 | 0 | 0 | 0 |
| EBITDA | (23,204) | (21,728) | (34,580) | (39,972) |
| Net Income | (26,961) | (24,774) | (38,371) | (44,434) |
| Total Assets | 32,503 | 44,595 | 26,259 | 66,833 |
| Total Debt | 33,735 | 45,534 | 18,956 | 28,466 |
Iterum Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Iterum Therapeutics Comparisons
Industry
Financing
Details
Iterum Therapeutics Competitors (105)
One of Iterum Therapeutics’s 105 competitors is Rhythm Pharmaceuticals, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Immuron | Corporation | Carlton, Australia | ||||
| TheraCryf | Formerly VC-backed | Nether Alderley, United Kingdom | ||||
| Nabriva Therapeutics | Formerly VC-backed | Dublin, Ireland | ||||
| Achaogen | Formerly VC-backed | South San Francisco, CA |
Iterum Therapeutics Signals
Iterum Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Iterum Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Iterum Therapeutics FAQs
-
When was Iterum Therapeutics founded?
Iterum Therapeutics was founded in 2015.
-
Where is Iterum Therapeutics headquartered?
Iterum Therapeutics is headquartered in Dublin, Ireland.
-
What is the size of Iterum Therapeutics?
Iterum Therapeutics has 9 total employees.
-
What industry is Iterum Therapeutics in?
Iterum Therapeutics’s primary industry is Pharmaceuticals.
-
Is Iterum Therapeutics a private or public company?
Iterum Therapeutics is a Public company.
-
What is Iterum Therapeutics’s stock symbol?
The ticker symbol for Iterum Therapeutics is ITRMF.
-
What is the current market cap of Iterum Therapeutics?
The current market capitalization of Iterum Therapeutics is $533.00.
-
What is Iterum Therapeutics’s current revenue?
The trailing twelve month revenue for Iterum Therapeutics is $390K.
-
Who are Iterum Therapeutics’s competitors?
Rhythm Pharmaceuticals, Immuron, TheraCryf, Nabriva Therapeutics, and Achaogen are some of the 105 competitors of Iterum Therapeutics.
-
What is Iterum Therapeutics’s annual earnings per share (EPS)?
Iterum Therapeutics’s EPS for 12 months was -$0.76.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process